How to Get a GLP-1 Covered by Insurance

Coverage for GLP-1 weight-management drugs is decided in three steps, and most people give up at the wrong one. First, whether your plan covers this category at all. Second, whether you meet the criteria it applies. Third, whether a denial is worth appealing — and sometimes it is not, because an exclusion and a denial are different things and only one of them can be argued with.

This is the mechanism, in the order it actually runs, with the questions that get you a straight answer at each stage. It will not promise you approval. What it will do is tell you quickly whether you are in a fight worth having, so you are not spending six weeks on an appeal against a plan that never covered the category.

Step one: is the category covered at all?

Before anything else, find out whether your plan excludes weight-management drugs as a class. Many employer plans do — particularly self-funded ones, where the employer rather than the insurer decides what is covered and is paying the claims directly. This is the single most important fact and the one most people discover last.

Ask the member-services line one precise question: “Does my plan cover drugs for chronic weight management, and if so which ones are on formulary and at what tier?” Vague questions get vague answers. Ask for it in writing, and ask for the plan document language rather than a summary.

Step two: the criteria, and the diagnosis that changes them

Where the category is covered, it almost always sits behind prior authorization: your prescriber has to justify the prescription before the plan will pay. The criteria vary by plan, but they are usually built from the same parts — a BMI threshold, sometimes a weight-related condition alongside it, sometimes documented prior attempts at weight loss, and sometimes a requirement to try a cheaper drug first.

• BMI threshold. Commonly 30, or 27 with a weight-related condition — the same structure the pivotal trials used for enrollment.
• Documented prior attempts. Some plans want a record of supervised weight-management effort. If you have one, it belongs in the request; if you do not, ask what counts before assuming you fail.
• Step therapy. Trying an older or cheaper drug first — usually Contrave or Qsymia. This is common and it is appealable when the required drug is contraindicated for you or has already failed.
• Continuation criteria. Approval is often for a limited period with a weight-loss threshold to renew. Ask what that threshold is at the start rather than discovering it at month six.

⭐ The most consequential thing you can know here: a different indication is a different conversation. Obstructive sleep apnea, established cardiovascular disease and type 2 diabetes each have completed outcomes trials behind them, and plans treat them differently from weight alone. If you have one of these — or suspect you might, particularly sleep apnea, which is widely undiagnosed — that is worth raising with your clinician before a weight-based request is filed. Our trial pages set out what each of those indications actually rests on.

Step three: if it is denied

1. Get the reason in writing. A denial notice must state a reason. That reason determines everything that follows, and a phone summary of it is not good enough.
2. Check whether it is an exclusion or a criteria failure. If the plan excludes the category, stop and change route. If you missed a criterion, find out precisely which one.
3. Fix the specific gap. Missing documentation is the most common and most fixable reason. A prior attempt that was not recorded, a comorbidity not coded, a BMI from the wrong date.
4. Ask for a peer-to-peer review. Your prescriber speaks to the plan’s reviewing clinician directly. It is often faster and more effective than a written appeal, and many prescribers will do it if asked.
5. Escalate to external review if internal appeals fail. Most plans are subject to an independent external review, which is decided outside the insurer. It is not a formality and it is not universally available — ask whether your plan is subject to it.

When cash beats the copay

Coverage is not automatically the cheaper route, and this is the arithmetic people skip. On a high-deductible plan you may pay the full brand price — frequently over $1,000 a month — until the deductible is met. Against that, compounded cash prices in this register run from about $79 a month for semaglutide and $99 for tirzepatide, with medians near $190 and $264.

That is not an argument for skipping insurance; a met deductible and a $25 copay beats everything. It is an argument for doing the sum before you assume. Our guide to the cash market sets out what the compounded route actually involves, including what you give up.

Common questions